[Federal Register Volume 61, Number 145 (Friday, July 26, 1996)]
[Notices]
[Pages 39153-39154]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-19019]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA No. 150F]
1996 Revised Aggregate Production Quotas for Controlled
Substances in Schedules I and II
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Not of final revised aggregate production quotas for 1996.
-----------------------------------------------------------------------
SUMMARY: This notice establishes revised 1996 aggregate production
quotas for controlled substances in Schedules I and II of the
controlled Substances Act (CSA).
EFFECTIVE DATE: July 26, 1996.
FOR FURTHER INFORMATION CONTACT:
Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section, Drug
Enforcement Administration, Washington, D.C. 20537, Telephone: (202)
307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826)
requires the Attorney General to establish aggregate production quotas
for controlled substances in Schedules I and II each year. This
responsibility has been delegated to the Administrator of the DEA
pursuant to Section 0.100 of Title 28 of the Code of Federal
Regulations. The Administrator, in turn, has redelegated this function
to the Deputy Administrator of the DEA pursuant to Section 0.104 of
Title 28 of the Code of Federal Regulations.
On May 23, 1996, a notice of the proposed revised 1996 aggregate
production quotas for controlled substances in Schedules I and II was
published in the Federal Register (61 FR 25895). All interested parties
were invited to comment on or object to these proposed aggregate
production quotas on or before June 24, 1996.
Several companies commented that the revised 1996 aggregate
production quotas for codeine (for sale), desoxyephedrine,
dextropropoxyphene, diphenoxylate, dihydrocodeine, hydrocodone (for
sale), hydromorphone, levorphanol, methylphenidate, noroxymorphone (for
sale), opium, oxycodone (for conversion) oxymorphone and pentobarbital
were insufficient to provide for the estimated medical, scientific,
research and industrial needs of the United States, for export
requirements and for the establishment and maintenance of reserve
stocks.
The DEA has reviewed the involved companies' 1995 year-end
inventories, their initial 1996 manufacturing quotas, 1996 export
requirements and their actual and projected 1996 sales. Based on this
data, the DEA has adjusted the revised 1996 aggregate production quotas
for desoxyephedrine, levorphanol, methylphenidate, noroxymorphone (for
sale), and pentobarbital to meet the estimated medical, scientific,
research and industrial needs of the United States.
Regarding codeine (for sale), dextropropoxyphene, dihydrocodeine,
diphenoxylate, hydrocodone (for sale), hydromorphone, opium, oxycodone
(for conversion) and oxymorphone, the DEA has decided that no
adjustments are necessary to meet the 1996 estimated medical,
scientific, research and industrial needs of the United States.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866. This action has been analyzed in accordance with
the principles and criteria contained in Executive Order 12612, and it
has been determined that this matter does not have sufficient
Federalism implications to warrant the preparation of a Federalism
Assessment.
The Deputy Administrator hereby certifies that this action will
have no significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et. seq.
The establishment of aggregate production quotas for Schedules I and II
controlled substances is mandated by law and by international treaty
obligations. While aggregate production quotas are of primary
importance to large manufacturers, their impact upon small entities is
neither negative nor beneficial. Accordingly, the Deputy Administrator
has determined that this action does not require a regulatory
flexibility analysis.
Therefore, under the authority vested in the Attorney General by
Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826),
delegated to the Administrator by Section 0.100 of Title 28 of the Code
of Federal Regulations, and redelegated to the Deputy Administrator of
the DEA by Section 0.104 of Title 28 of the Code of Federal
Regulations, the Deputy Administrator
[[Page 39154]]
hereby orders that the 1996 revised aggregate production quotas,
expressed in grams of anhydrous acid or base, be established as
follows:
------------------------------------------------------------------------
Established
Basic class revised 1996
quotas
------------------------------------------------------------------------
Schedule I:
Acetylmethadol.......................................... 7
Alphacetylmethadol...................................... 7
Aminorex................................................ 7
Cathinone............................................... 9
Difenoxin............................................... 14,000
Dihydromorphine......................................... 7
2,5-Dimethoxyamphetamine................................ 10,650,000
Dimethylamphetamine..................................... 7
Ethylamine analog of Phencyclidine...................... 5
N-Ethylamphetamine...................................... 7
Heroin.................................................. 5
Lysergic acid diethylamide.............................. 58
Mescaline............................................... 7
Methaqualone............................................ 17
Methcathinone........................................... 9
4-Methoxyamphetamine.................................... 17
4-Methylaminorex........................................ 2
3,4-Methylenedioxy-
amphetamine............................................. 17
3,4-Methylenedioxy-N-ethylamphetamine................... 27
3,4-Methylenedioxy-
methamphetamine......................................... 42
3-Methylfentanyl........................................ 14
Normethadone............................................ 7
Normorphine............................................. 7
Psilocybin.............................................. 2
Psilocyn................................................ 2
Tetrahydrocannabinols................................... 55,100
Schedule II:
Alfentanil.............................................. 8,500
Amobarbital............................................. 301,000
Amphetamine............................................. 2,280,000
Cocaine................................................. 550,040
Codeine (for sale)...................................... 47,000,000
Codeine (for conversion)................................ 17,519,000
Desoxyephedrine \1\..................................... 1,755,100
Dextropropoxyphene...................................... 118,066,000
Dihydrocodeine.......................................... 214,000
Diphenoxylate........................................... 1,002,000
Ecogonine (for conversion).............................. 650,100
Ethylmorphine........................................... 12
Fentanyl................................................ 143,000
Hydrocodone (for sale).................................. 12,145,000
Hydrocodone (for conv).................................. 2,800,000
Hydromorphone........................................... 718,000
Isomethadone............................................ 12
Levo-alpha-acetylmethadol............................... 200,000
Levorphanol............................................. 17,000
Meperidine.............................................. 10,822,000
Methadone............................................... 4,551,000
Methadone (for conv).................................... 364,000
Methadone Int. (for conv)............................... 5,534,000
Methamphetamine (for conv).............................. 723,000
Methylphenidate......................................... 11,775,100
Morphine (for sale)..................................... 12,450,000
Morphine (for conv)..................................... 76,735,000
Noroxymorphone (for sale)............................... 27,000
Noroxymorphone (for conv)............................... 3,400,000
Opium................................................... 714,000
Oxycodone (for sale).................................... 5,571,000
Oxycodone (for conv).................................... 37,300
Oxymorphone............................................. 11,200
Pentobarbital........................................... 18,000,000
Phencyclidine........................................... 40
Phenylacetone (for conv)................................ 10
1-Phenylcyclohexylamine................................. 10
1-Piperidinocyclo-
hexanecarbonitrile...................................... 12
Secobarbital............................................ 400,000
Sufentanil.............................................. 1,000
Thebaine................................................ 9,387,000
------------------------------------------------------------------------
\1\ 1,700,00 grams of levo-desoxyephedrine for use in a non-controlled,
non-prescription product and 55,100 grams for methamphetamine.
Dated: July 18, 1996.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 96-19019 Filed 7-25-96; 8:45 am]
BILLING CODE 4410-09-M
